ERBB2 and breast cancer: We used a validation cohort of BC patients to establish a new DEPArrayTM-PT-HER2-FISH workflow for further application in a development cohort, characterized as PT-HER2-negative but CTC-HER2/neu-positive, to identify patients with PT-HER2 amplified cells not detected by routine pathology.